KLK3 and prostate cancer: The primary validation of the assay was performed in a cohort of 740 patients from the Gothenburg arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC), comprising patients with a PSA of 3-10 ng/ml who did not undergo screening (15).